Modifiedmedical mutual - ohioPolicy AHS - G2124 - Serum Tumor Markers for Malignancies

Serum Tumor Markers for Malignancies

Defines coverage criteria for serum tumor marker tests used to detect, work up, monitor, or surveil various malignancies for members of Medical Mutual - Ohio; includes covered indications, frequency limits for specified markers, coding updates, and exclusions.

Policy Summary

Payermedical mutual - ohio

PolicySerum Tumor Markers for Malignancies

Policy CodePolicy AHS - G2124 - Serum Tumor Markers for Malignancies

Change TypeTerminology, coding, and indication updates

Effective DateOct 15, 2025

Next Review DateN/A

Key ActionVerify member benefits and use updated CPT codes (0558U, 0559U) and revised test indications when ordering or submitting claims.

SourceLink

POLICY UPDATE CHANGES

Adjusted terminology from 'serum tumor markers' to 'serum biomarkers' to broaden definition to include related serum markers more accurately described as biomarkers.

Removed LDH section since LDH is a broad marker beyond serum tumor biomarker designation.

Added CPT codes 0558U and 0559U (effective 7/1/2025) and removed CPT code 83615.

Updated multiple biomarker indications (examples include ALP, B2M, BNP/NT-proBNP, CA19-9, CA-125, CEA, HE4, Inhibin, serum free light chains) — adding, removing, or reassigning specific indications and surveillance/workup designations.

dozenstumor markers addressed

quarterlydefault follow-up frequency

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

3–6moAFP surveillance example

Coverage Criteria and Clinical Indications

Covered Indications (list)

Measurement of the listed serum biomarkers MEETS COVERAGE CRITERIA when used for the specified indications (quoted from policy):

Covered marker-indication pairs: ALP: workup for bone neoplasms; workup for melanoma (uveal). AFP: HCC — screening, workup, and surveillance (every 3–6 months for 2 years, then every 6 months); intrahepatic cholangiocarcinoma — workup for isolated intrahepatic mass; occult primary — additional workup for localized adenocarcinoma or carcinoma NOS (liver, mediastinum, retroperitoneal mass); ovarian/fallopian tube/primary peritoneal cancer — initial workup, during primary chemotherapy, monitoring/follow-up for complete response (as clinically indicated); multiple ovarian subtypes — monitoring/follow-up as listed; testicular cancer (nonseminoma) — workup, risk classification, surveillance (no more than every 2 months); testicular cancer (pure seminoma) — initial diagnostic workup, post-diagnostic workup, risk classification, post-treatment surveillance (no more than every 2 months); thymomas/thymic carcinomas — initial evaluation if appropriate.

Frequencies included where specified in policy chunks.

Hematologic and plasma cell markers: Beta-2 microglobulin (B2M): workup for B-cell lymphomas (DLBCL, follicular grade 1–2, HIV-related, lymphoblastic, mantle cell), workup for Castleman disease, workup for CLL/SLL for prognostic/therapy determination. Serum free light chains (kappa/lambda): workup and follow-up for multiple myeloma (initial diagnostic workup; follow-up; surveillance up to once per month), workup for systemic light chain amyloidosis, workup for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.

Includes Castleman disease and surveillance frequency where specified.

Cardiac and amyloidosis markers: BNP/NT-proBNP: initial diagnostic workup in multiple myeloma to assess cardiac involvement; Troponin T: initial diagnostic workup for systemic light chain amyloidosis. Tryptase: initial diagnosis for systemic mastocytosis.

Markers inform cardiac involvement and prognosis; see policy for assay limitations.

Thyroid and neuroendocrine markers: Calcitonin (CALCA): workup for medullary carcinoma and related indications, postoperative evaluation and monitoring (2–3 months postoperative, then every 6–12 months); Chromogranin A (CgA): evaluation for suspected neuroendocrine tumors (variable sensitivity/specificity influenced by confounders).

Routine calcitonin screening for thyroid nodules is controversial per ATA guidance.

Gynecologic and gonadal markers: CA-125: workup for appendiceal adenocarcinoma, Lynch syndrome surveillance, occult primary evaluation, ovarian/fallopian tube/primary peritoneal cancer — initial workup, during primary chemotherapy, monitoring/follow-up (if initially elevated use at visits); HE4: ovarian/fallopian tube/primary peritoneal cancer — initial workup, during primary chemotherapy, monitoring/follow-up; Inhibin (INHA): occult primary additional workup; ovarian indications as listed; CGB3 (beta-hCG): gestational trophoblastic neoplasia — initial, during and post treatment (no more than weekly), follow-up (no more than monthly for 12 months); ovarian cancer indications as listed.

Surveillance cadence for germ cell and ovarian contexts specified in policy.

Gastrointestinal and hepatopancreatobiliary markers: CA19-9: workup and surveillance for ampullary adenocarcinoma (every 3–6 months for 2 years, then every 6–12 months up to 5 years as indicated); baseline/monitoring for pancreatic adenocarcinoma (post-op surveillance every 3–6 months for 2 years then every 6–12 months as indicated); CA19-9 and CA-125: workup for intra- and extrahepatic cholangiocarcinoma, gallbladder, appendiceal adenocarcinoma, occult primary as listed; AFP: HCC surveillance in high-risk patients per AASLD/ADLM guidance.

Frequencies included where specified.

Breast and colorectal markers: CA15-3/27.29: monitoring metastatic breast cancer; CEA: appendiceal adenocarcinoma baseline/monitoring/post-treatment surveillance, breast cancer (invasive) — monitoring metastatic disease, colon cancer — baseline/monitoring/surveillance (every 3–6 months for 2 years, then every 6 months to 5 years).

ER/PR/HER2 remain required in breast cancer; circulating markers used adjunctively.

Miscellaneous markers: Troponin (quantitative troponin) and other listed analytes as indicated in the policy table for the specific clinical contexts above; measurement should follow the marker-specific indications and frequencies described in the policy.

Refer to policy table for full, test-specific indication rows.

Guideline-based coverage criteria

Coverage and clinical-use statements summarized from professional society guidance; treat as condition-specific recommendations.

Germ cell tumors (ASCO): Do not use serum tumor markers to screen asymptomatic individuals for germ cell tumors. Measure AFP and hCG before orchiectomy to establish baseline (but not to decide orchiectomy). Measure AFP, hCG, and LDH shortly after orchiectomy and before subsequent treatment; before chemotherapy for mediastinal/retroperitoneal NSGCTs; immediately prior to chemotherapy for stage II/III NSGCT; prior to RPLND in stage I/II NSGCT; at the start of each chemotherapy cycle and when chemotherapy concludes. Continue surveillance with AFP and hCG for 10 years after definitive therapy.surveillance duration 10 years

ASCO guideline summary; see chunks 54-55

Seminoma (ASCO): No serum markers guide treatment decisions for seminoma; measure hCG and AFP at treatment conclusion and during post-treatment surveillance at intervals: every 2–4 months in year 1; every 3–4 months in year 2; every 4–6 months in years 3–4; annually thereafter — surveillance at least 10 years.surveillance intervals specified

ASCO recommendations; chunk 55

Numerous marker-specific indications are covered

Numerous marker-specific indications are covered. Nodes list individual markers with their primary covered uses and frequencies where specified.

AFP: Uses: HCC screening/workup/surveillance (every 3–6 months for 2 years then every 6 months); intrahepatic cholangiocarcinoma workup; occult primary workup; ovarian/fallopian tube/primary peritoneal cancer initial workup, during primary chemotherapy, monitoring/follow-up; testicular cancer (nonseminoma and seminoma) workup, risk classification, and surveillance per listed cadences.>20 μg/L prompts further investigation (per ADLM)

See chunks 4, 6, 31, 57 for details.

CA-125: Uses: Appendiceal adenocarcinoma baseline/workup; Lynch syndrome surveillance; occult primary evaluation; ovarian/fallopian tube/primary peritoneal cancer — initial workup, during chemotherapy, monitoring/follow-up (if initially elevated consider every visit monitoring).

Chunks 8, 10, 12

CEA: Uses: Appendiceal adenocarcinoma baseline/monitoring/post-treatment surveillance; breast cancer (invasive) — monitoring metastatic disease; colon cancer — baseline/monitoring/surveillance (every 3–6 months for 2 years then every 6 months to 5 years); extrahepatic cholangiocarcinoma, gallbladder cancer, intrahepatic cholangiocarcinoma — workup and monitoring; medullary thyroid cancer — diagnosis and monitoring post-surgery.

Use cases for biomarkers (diagnostic, prognostic, predictive, monitor)

Serum biomarkers may be used across four clinical roles. The policy permits use consistent with analytic/clinical validity and guideline recommendations.

Diagnostic: Use to aid in diagnosis or subclassification of a disease (e.g., calcitonin for suspected medullary thyroid carcinoma; serum free light chains with SPEP/IFE to detect monoclonal processes).

See chunks 26, 37, 45

Prognostic: Use to estimate prognosis independent of treatment (e.g., elevated B2M associated with worse survival in lymphomas; elevated CgA or pancreastatin may be prognostic in NETs).

Chunks 35, 43

Predictive/Companion: Use to predict therapy response or identify patients for specific treatments (e.g., ER/PR/HER2 in breast cancer are required companion predictive tests; some multianalyte assays inform referral decisions for adnexal masses per FDA/NCCN context).

Chunks 26, 52, 53

Specific markers discussed with typical clinical roles

Selected markers and their typical clinical roles as discussed in the policy:

ALP: Role: Evaluation in workup of bone neoplasms and to support assessment of bone or hepatic involvement (e.g., systemic light chain amyloidosis liver involvement).

Chunk 30

AFP: Role: Detection and surveillance of hepatocellular carcinoma; used in workup of intrahepatic lesions, certain ovarian and testicular tumors; prognostic information in untreated HCC.>20 μg/L prompts further investigation (per ADLM)

Chunks 31, 57

B2M: Role: Prognostic marker in hematologic malignancies (e.g., diffuse large B-cell lymphoma, CLL/SLL) and workup for Castleman disease.

Chunk 35

Cardiac involvement assessment in amyloidosis/multiple myeloma and serum free light chains

Assessment of cardiac involvement and use of serum free light chains in plasma cell disorders:

Cardiac involvement in amyloidosis/multiple myeloma: Troponin T: initial diagnostic workup for systemic light chain amyloidosis. BNP/NT-proBNP: assess cardiac involvement in multiple myeloma as part of initial diagnostic evaluation. These markers may inform extent of involvement and prognosis; be aware of inter-assay variability and limitations.

Chunks 15, 36, 47

Serum free light chains for plasma cell disorders: Indications: Use with serum protein electrophoresis and immunofixation for screening suspected malignant monoclonal processes (MM, Waldenström, AL amyloidosis, MGRS); baseline prognostic measurement and for monitoring specific scenarios (e.g., oligosecretory MM, AL amyloidosis) with surveillance frequency up to once per month as clinically indicated.up to once per month

Chunks 15, 57, 45

Evaluation for medullary thyroid carcinoma when clinically suspected

Evaluation for medullary thyroid carcinoma when clinically suspected:

Calcitonin for suspected MTC: Measure serum calcitonin when medullary thyroid carcinoma is suspected or for diagnostic workup of relevant thyroid masses; calcitonin correlates with tumor mass and is used for postoperative monitoring (measure calcitonin, CEA, TFTs, TSH every 6–12 months per ATA guidance).postoperative monitoring 2–3 months then every 6–12 months

Chunks 6, 37, 63

Evaluation of suspected neuroendocrine tumors using chromogranin A

Use of chromogranin A for suspected neuroendocrine tumors with noted limitations:

Chromogranin A (CgA): CgA may be measured in the evaluation of suspected neuroendocrine tumors but has variable sensitivity and is influenced by confounders (e.g., proton pump inhibitors, atrophic gastritis, renal insufficiency). Elevated levels may be prognostic, but CgA and pancreastatin are not recommended for routine treatment-guiding use; interpret results in clinical context and alongside imaging.

Chunks 43, 61

Germ cell tumors (AFP, hCG, LDH)

Germ cell tumor markers (AFP, hCG, LDH) are covered for diagnosis, staging, monitoring, and surveillance with timing per guideline recommendations.

Pre-treatment and perioperative measurement: Measure AFP and hCG prior to orchiectomy to establish baseline; measure AFP, hCG, and LDH shortly after orchiectomy and before subsequent treatment as recommended by ASCO; measure prior to retroperitoneal lymph node dissection in stage I/II NSGCTs.

Chunks 54-55

During chemotherapy and post-treatment: Measure AFP and hCG at the start of each chemotherapy cycle and when chemotherapy concludes; measure immediately prior to chemotherapy for stage II/III NSGCT and for mediastinal/retroperitoneal NSGCT to guide risk stratification.

Chunk 54

Surveillance timing (ASCO): Surveillance intervals for seminoma and NSGCT: Year 1 every 2–4 months; Year 2 every 3–4 months; Years 3–4 every 4–6 months; annually thereafter — continue surveillance for at least 10 years after definitive therapy. For certain ovarian malignant germ cell tumors, surveillance no more than every 2 months in first 2 years per ovarian surveillance guidance.year-based intervals as specified

Hepatocellular carcinoma surveillance (AFP, AFP-L3%, DCP)

Hepatocellular carcinoma surveillance and use of AFP (and related markers):

HCC surveillance in high-risk patients: ADLM recommends AFP measurement in managing HCC; for surveillance in high-risk patients measure AFP at 6-month intervals. AASLD advises diagnosis based on imaging or pathology and considers AFP supplemental; AFP-L3% and DCP are promising but not routinely recommended outside validated settings.AFP every 6 months; AFP >20 μg/L prompts further investigation

Chunks 57, 62

Breast and ovarian cancer biomarker usage

Breast and ovarian cancer biomarker roles — diagnostic, surgical planning and monitoring rather than screening:

Breast cancer biomarkers: ER/PR testing should be performed in all breast cancer patients and HER2 in all invasive disease; circulating markers (CEA, CA15-3, CA27.29) may be used adjunctively in metastatic breast cancer but are insufficient alone to direct therapy or replace biopsy/molecular testing.

Chunk 59

Ovarian cancer biomarkers: CA-125 is not recommended for population screening in asymptomatic women except in those with hereditary risk (used with transvaginal ultrasound); CA-125, HE4, OVA1/Overa/ROMA may be used to assess adnexal masses, assist referral decisions, and to monitor response when initially elevated — they should not be used as sole determinants precluding specialist evaluation.

Chunks 59, 52-53

Neuroendocrine tumor markers (CgA, pancreastatin)

Neuroendocrine tumor markers and limitations:

CgA and pancreastatin may be prognostic in advanced unresectable/metastatic GEP-NETs, but thresholds and treatment-informing value are unclear. These markers are influenced by PPIs and comorbidities; routine ordering to guide therapy is not recommended.

Chunks 61, 43

Plasma cell disorders — serum free light chains

Plasma cell disorders — recommended use of serum free light chains with other protein assays:

Screening and diagnosis: Order serum free light chain testing with serum protein electrophoresis and immunofixation when screening patients suspected of a malignant monoclonal process (multiple myeloma, Waldenström, AL amyloidosis, MGRS).

Chunks 60, 45

Monitoring: Use serum free light chains for baseline prognosis and for monitoring scenarios such as oligosecretory multiple myeloma and AL amyloidosis; surveillance frequency may be up to once per month as clinically indicated. Be aware of assay performance differences between tests.up to once per month

Chunks 15, 47

Multiple biomarker-specific indications updated

Multiple biomarker-specific indication updates and table revisions summarized in policy history.

Updated/adjusted indications: Policy revisions added, removed, or clarified numerous test-specific indications: ALP additions (uveal melanoma), B2M split to include Castleman disease as separate row, CA-125 and CA19-9 monitoring/workup adjustments, HE4 added for ovarian-related cancers, INHA modified to add occult primary indications, serum free light chains updated to include follow-up for multiple myeloma, and LDH section removed. Refer to the policy table for full test-specific rows.

Chunks 88-90 contain revision history details.

Not Medically Necessary / Not Covered

Not covered / does not meet coverage criteria:

Not covered: 1) Use of the listed biomarkers for cancer indications not discussed in this policy DOES NOT MEET COVERAGE CRITERIA; 2) All other serum tumor markers not addressed in the policy DO NOT MEET COVERAGE CRITERIA; 3) Analysis of proteomic patterns in serum for screening or detection of cancer DOES NOT MEET COVERAGE CRITERIA.

Explicit exclusions per policy chunk 16.

Proteomic pattern analysis of serum is considered investigational in this policy. The policy explicitly states that "analysis of proteomic patterns in serum for screening or detection of cancer DOES NOT MEET COVERAGE CRITERIA." Proteomic approaches remain under investigation and are not established as validated, covered clinical tests for cancer screening or detection at this time.

Not covered: the policy designates that proteomic pattern analysis in serum for cancer screening and the use of any serum tumor markers or tumor-marker indications that are not specifically listed in the policy DOES NOT MEET COVERAGE CRITERIA. Providers should not expect coverage for tumor marker testing used for cancer indications that are not explicitly addressed in the listed coverage criteria.

AFP-L3% and des-gamma-carboxy prothrombin (DCP) are noted as emerging HCC-related biomarkers but the policy highlights that, when used alone, "AFP-L3% and DCP have insufficient sensitivity to detect early-stage HCC." Accordingly, routine standalone use of AFP-L3% or DCP for early HCC surveillance is not supported as sufficient to meet coverage criteria.

The policy excludes routine measurement of biomarkers that lack sufficient clinical validation or guideline support. Examples cited include markers for which ADLM or other societies do not recommend routine use (for example, Glypican-3 for HCC and multiple proposed bladder-cancer markers), and other nonspecific or unvalidated markers. Proteomic-identified candidates remain investigational and require further study before routine clinical use.

Lactate dehydrogenase (LDH) is no longer presented as a serum tumor biomarker in this policy. The revision history documents removal of the LDH section because LDH is considered a broad laboratory marker beyond the scope of designated serum tumor biomarkers; use of LDH as an STM is not supported within this policy.

Testing Frequency and Surveillance Cadence

Designated serum biomarkers — permitted frequencies

Default permitted frequencyQuarterly measurement of designated serum biomarkers is permitted for follow-up, monitoring, and/or surveillance except where otherwise specified.

AFP (general HCC/ovarian/testicular uses)Surveillance: every 3–6 months for 2 years, then every 6 months (HCC and certain post-treatment ovarian indications); Testicular nonseminoma surveillance: no more than every 2 months; ovarian borderline tumors: every visit if initially elevated.

CA19-9Post-operative/post-adjuvant surveillance after pancreatic adenocarcinoma: every 3–6 months for 2 years, then every 6–12 months as clinically indicated (policy notes similar cadences).

Serum free light chainsSurveillance/monitoring: up to once per month for multiple myeloma and related plasma cell disorders (frequency as clinically indicated).

Gestational trophoblastic beta-hCGDuring treatment: no more than weekly; follow-up after treatment: no more than monthly for 12 months.

Procedure Codes and Billing

Listed CPT/HCPCS Codes (general and tumor marker-specific)mixed

81479	Unlisted molecular pathology procedure.
81500	Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score (ROMA).
81503	Oncology (ovarian), biochemical assays of five proteins (OVA1), algorithm reported as a risk score.
81538	Oncology (lung), mass spectrometric 8-protein signature (VeriStrat®).
81599	Unlisted multianalyte assay with algorithmic analysis.
82105	Alpha-fetoprotein (AFP); serum.
82107	Alpha-fetoprotein (AFP); AFP-L3 fraction isoform and total AFP (including ratio).
82232	Beta-2 microglobulin.
82308	Calcitonin.
82378	Carcinoembryonic antigen (CEA).

1–10 of 23

1/3

Additional quantitative immunoassay and proprietary codesmixed

84999	Unlisted chemistry procedure.
86300	Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29).
86301	Immunoassay for tumor antigen, quantitative; CA 19-9.
86304	Immunoassay for tumor antigen, quantitative; CA 125.
86305	Human epididymis protein 4 (HE4).
86316	Immunoassay for tumor antigen, other antigen, quantitative (eg, CA 50, 72-4, 549).
86336	Inhibin A, each.
0003U	Oncology (ovarian) biochemical assays of five proteins (Overa™).
0163U	Oncology (colorectal) screening, ELISA of 3 plasma/serum proteins with algorithm (BeScreened™-CRC).
0404U	Oncology (breast), semiquantitative thymidine kinase activity by immunoassay (Divitum®Tka).

1–10 of 12

1/2

Policy coding updatesCPT

0558U	CPT added (effective 7/1/2025)
0559U	CPT added (effective 7/1/2025)
83615	CPT code removed

AFP for HCC screening — operational trigger

AFP threshold triggerAFP concentration >20 μg/L should prompt further investigation even if ultrasound is negative.

Context of useADLM recommends AFP measurement at 6-month intervals for high-risk HCC screening; sustained increases may be used with ultrasound to inform detection and management.

Diagnostic roleAFP concentrations can provide prognostic information in untreated patients and are recommended for monitoring disease in HCC.

Provider Requirements, Authorization, and Ordering Guidance

Prior Authorization

Prior Authorization Required for Proprietary/Proprietary-Code Tests

Prior authorization is required for proprietary/commercial multibiomarker or algorithmic serum tests (e.g., Ova1®, Overa™, Ova1Plus®, OvaWatch SM, BeScreened™-CRC, VeriStrat®, REVEAL, and other branded assays) and for tests billed with unlisted or proprietary CPT/HCPCS codes. Requests must include clinical indication, prior imaging/assessment results when applicable, and documentation that the test result will influence management. Quarterly measurement is generally permitted for follow-up/monitoring/surveillance unless otherwise specified.

Affected proprietary assays: Ova1®, Overa™ (OVA1 Next Generation), Ova1Plus®, OvaWatch SM, BeScreened™-CRC, VeriStrat®, REVEAL, and similar branded/multianalyte algorithmic tests.
Unlisted/proprietary CPTs subject to review prior to payment (examples in CPT list: 0003U, 0163U, 0140U/0558U/0559U and other U-codes; see CPT code table).
Prior authorization must document that testing is consistent with the clinical indications in this policy and that results will affect clinical management or referral. Verification of member benefits and applicable state/federal regulations is required before ordering.

Ordering, Documentation, and Test Performance

Note

Verify member benefits (coverage depends on plan)

Confirm individual member benefits at the time of the request; coverage of tests depends on the member's specific benefit plan.

Note

Ordering provider authority — consult full policy

No explicit ordering‑provider restrictions are specified in the extracted text; ordering authority details are provided in the full policy online — consult the full policy for any applicable ordering provider requirements.

Documentation Required

Document reason for testing and referral plan

Ordering clinicians should document the medical reason for testing and whether the patient will be referred to a specialist (particularly for adnexal masses); include the indication and intended referral plan in the medical record.

Document indication (e.g., evaluation of adnexal/pelvic mass) and referral intent.

Definitions, Terminology, and Scientific Background

Background: Circulating tumor biomarkers are substances measurable in blood or other body fluids that are produced by tumors or generated in response to tumor presence. They can aid detection, diagnosis, staging, prognostication, and monitoring for some cancers, but analytic and clinical validity and clinical utility vary widely by marker. Proteomic methods and many candidate biomarkers remain investigational and have limited evidence for routine screening or surveillance. Professional society guidance (for example ADLM, NANETS) endorses selective use of validated markers (such as AFP in high-risk HCC, AFP/hCG in germ cell tumors, or free light chains in plasma cell disorders) while advising against routine use of nonspecific or unvalidated markers.

Definition — circulating tumor biomarkers

DefinitionCirculating tumor biomarkers: substances detected in blood, urine, or other body fluids produced by a tumor or in response to its presence; amounts are typically elevated in individuals harboring a tumor.

Sample matrixThis policy addresses biomarkers measurable in an individual's serum.

Clinical usesThese biomarkers can assist with detection, diagnosis, staging, and management of some cancers when used in the appropriate clinical context.

Not Medically Necessary / Investigational

Not covered: Proteomic pattern analysis in serum for cancer screening and detection is explicitly excluded. The policy states that analysis of proteomic patterns for screening or detection "DOES NOT MEET COVERAGE CRITERIA" and that serum tumor markers or indications not specifically addressed in the policy are not covered.

Not covered: The policy notes that although AFP-L3% and DCP are emerging HCC-related biomarkers with greater specificity, professional guidance cautions that "AFP-L3% and DCP have insufficient sensitivity to detect early-stage HCC when used alone." Therefore, routine standalone use of these markers for early HCC surveillance is not supported by the policy.

Not covered: Proteomic analyses performed on serum remain investigational. The document describes proteomics as a research technique still under investigation and therefore not established as a covered clinical method for cancer detection or routine patient management.

Not covered: Routine measurement of biomarkers that lack supporting evidence or guideline endorsement is not covered. The policy cites examples such as Glypican-3 (for HCC) and numerous proposed bladder-cancer or other nonspecific markers, and reiterates that nonspecific or unvalidated markers should not be used routinely to guide treatment or surveillance outside research settings.

Not covered: The policy removed LDH from the serum tumor biomarker sections and clarifies that LDH is a broad laboratory marker rather than a designated serum tumor biomarker. As such, the policy does not support use of LDH as an STM for coverage purposes.

Policy Update History

2025-06-04content_update

Reviewed and updated background, guidelines, recommendations, and evidence references; adjusted terminology from 'serum tumor markers' to 'serum biomarkers' and changed table title to 'Serum Biomarkers'; multiple individual marker indications were added, removed, or clarified (ALP, B2M, CGB3/beta-hCG, BNP/NT-proBNP, CA19-9, CA-125, HE4, Inhibin, serum free light chains, and others).

2025-06-04structural_change

Multiple table rows updated including removal of 'during treatment, surveillance' for ALP, addition of 'Melanoma (uveal)' for ALP, separation of Castleman disease into its own B2M row, and retitling beta-hCG to Chorionic gonadotropin beta polypeptide (CGB3) with related occult primary wording changes.

Policy Summary

Payermedical mutual - ohio

PolicySerum Tumor Markers for Malignancies

Policy CodePolicy AHS - G2124 - Serum Tumor Markers for Malignancies

Change TypeTerminology, coding, and indication updates

Effective DateOct 15, 2025

Next Review DateN/A

Key ActionVerify member benefits and use updated CPT codes (0558U, 0559U) and revised test indications when ordering or submitting claims.

SourceLink

On This Page

Hepatocellular carcinoma (ADLM / AASLD): ADLM recommends AFP measurement when managing HCC and recommends AFP surveillance at 6-month intervals in high-risk patients; AFP concentrations >20 μg/L should prompt further investigation. AASLD notes AFP-L3% and DCP are promising but advises against routine use of biomarkers other than AFP for surveillance outside validated settings; diagnosis should be based on imaging or pathology with biomarkers supplemental.

ADLM and AASLD guidance; chunks 57 and 62

Colorectal cancer (ADLM): ADLM recommends CEA measurement every 3 months in stage II/III patients who are candidates for surgery or systemic therapy of metastatic disease; preoperative CEA may assist surgical planning; CEA not recommended for screening asymptomatic individuals.

ADLM guidance; chunk 57

Breast cancer (ADLM / ASCO): ADLM recommends ER/PR testing in all breast cancer patients and HER2 in all invasive disease. CEA, CA15-3, CA27.29 may be used as adjuncts in metastatic breast cancer but are insufficient alone to monitor response or direct therapy. No additional circulating biomarkers have demonstrated utility to change systemic therapy decisions beyond ER/PR/HER2.

Chunks 55 and 59

Ovarian cancer (ADLM / NCCN context): CA-125 screening is not recommended for asymptomatic women except with hereditary risk where CA-125 plus transvaginal ultrasound may be used; CA-125 is useful to help distinguish benign from malignant adnexal masses and to monitor chemotherapeutic response and follow-up if initial values were elevated. HE4/OVA1/ROMA have defined roles in evaluating adnexal masses and monitoring per guideline context but should not replace specialist evaluation.

Chunk 59 and NCCN references in policy table

Neuroendocrine tumors (NANETS): Significantly elevated CgA or pancreastatin may be prognostic but thresholds are unclear; changes rarely inform treatment and these nonspecific markers are not recommended for routine use to guide therapy.

Chunk 61

Plasma cell disorders and free light chains (ADLM): Order serum free light chain testing with SPEP and immunofixation when screening for suspected malignant monoclonal processes (MM, Waldenström, AL amyloidosis, MGRS). Use free light chains for baseline prognosis and for monitoring specific scenarios (e.g., oligosecretory MM, AL amyloidosis).

Chunks 60 and 57

CA19-9: Uses: Ampullary adenocarcinoma — workup and surveillance (every 3–6 months for 2 years then every 6–12 months up to 5 years); appendiceal, extrahepatic cholangiocarcinoma, gallbladder, intrahepatic cholangiocarcinoma — baseline/monitoring; pancreatic adenocarcinoma baseline/monitoring/post-op surveillance per cadences.

Chunks 6, 8

HE4: Uses: Ovarian/fallopian tube/primary peritoneal cancer — initial workup, during primary chemotherapy, monitoring/follow-up for complete response (as clinically indicated).

Chunk 14

INHA (Inhibin): Uses: Occult primary additional workup for adenocarcinoma or carcinoma NOS; ovarian cancer initial workup, during chemotherapy, monitoring/follow-up.

Chunk 14

B2M: Uses: Workup for B-cell lymphomas (DLBCL, follicular grade1–2, HIV-related, lymphoblastic, mantle cell); workup for Castleman disease; workup for CLL/SLL for prognostic and therapy determination.

Chunk 5

Serum free light chains (SFL): Uses: Castleman disease workup; multiple myeloma initial diagnostic workup, follow-up and surveillance (up to once per month); systemic light chain amyloidosis initial diagnostic workup.

Chunks 15, 45, 47

BNP/NT-proBNP: Uses: Assessment in multiple myeloma initial diagnostic workup to evaluate cardiac involvement; (note: BNP/NT-proBNP indications adjusted in revision history — troponin T moved for amyloidosis).

Chunks 6, 88

Calcitonin: Uses: Evaluation for medullary thyroid carcinoma — diagnosis, additional workup, post-surgical evaluation, monitoring and surveillance (2–3 months postoperative, then every 6–12 months).

Chunks 6, 37, 63

Troponin T: Uses: Initial diagnostic workup for systemic light chain amyloidosis (cardiac involvement assessment).

Chunk 15

CA15-3 / CA27.29: Uses: Monitoring metastatic breast cancer as adjunct markers; not for population screening.

Chunk 6

CGB3 (beta-hCG): Uses: Gestational trophoblastic neoplasia — initial workup, during and post treatment (no more than weekly), follow-up/surveillance (no more than monthly for 12 months); occult primary and ovarian indications in select contexts.

Chunk 12

Chromogranin A, Pancreastatin: Uses: Evaluation/prognostication in neuroendocrine tumors with limitations; not recommended for routine treatment guidance due to variability and confounders (e.g., PPIs).

Chunks 43, 61

Tryptase: Uses: Initial diagnosis of systemic mastocytosis.

Chunk 15

Monitoring / Surveillance: Use to monitor treatment response or detect recurrence (e.g., CEA in colorectal cancer every 3 months; AFP surveillance cadence for HCC; AFP/hCG schedule for germ cell tumor surveillance).

BNP / NT-proBNP: Role: Markers of cardiac involvement and dysfunction; used in assessment or monitoring of cardiac involvement in systemic light chain amyloidosis and multiple myeloma.

Calcitonin: Role: Primary marker for medullary thyroid carcinoma — correlates with tumor mass; used for postoperative monitoring and surveillance within specified intervals.

Chunk 37

AFP and hCG — ASCO surveillance guidance (nonseminomatous germ cell tumors)

Pre-orchiectomy baselineMeasure serum AFP and hCG before orchiectomy to establish diagnosis and baseline levels.

Post-orchiectomy and pre-treatmentMeasure AFP, hCG, and LDH shortly after orchiectomy and before any subsequent treatment for NSGCTs.

Surveillance duration and intervalsMeasure AFP and hCG during surveillance for 10 years after definitive therapy; intervals as specified for post-treatment surveillance (see next item).

ASCO surveillance cadence (NSGCT post-treatment)Surveillance intervals: every 2–4 months in year 1; every 3–4 months in year 2; every 4–6 months in years 3–4; annually thereafter (continue for at least 10 years).

AFP — surveillance frequency for HCC/high-risk patients

HCC high-risk surveillance intervalAFP measurement at 6-month intervals for patients at high risk for hepatocellular carcinoma.

AFP surveillance cadence exampleSurveillance: every 3–6 months for 2 years, then every 6 months for some indications (policy lists this cadence for certain AFP uses including HCC and some ovarian indications).

Action on sustained risesSustained increases in AFP may be used with ultrasound to inform detection and management of HCC.

hCG and AFP — seminoma and NSGCT surveillance cadence

Seminoma and NSGCT surveillance — Year 1Measure hCG and AFP every 2–4 months in the first year after treatment.

Year 2Measure hCG and AFP every 3–4 months in the second year.

Years 3–4Measure hCG and AFP every 4–6 months in the third and fourth years.

ThereafterMeasure hCG and AFP annually thereafter; surveillance should continue for at least 10 years following conclusion of therapy.

CEA — surveillance frequency

CEA surveillance frequencyEvery 3 months (for example, in stage II/III colorectal cancer surveillance where CEA measurement is indicated).

Use case noteCEA is not recommended for population screening of asymptomatic individuals; use is for surveillance and in patients who are candidates for further therapy.

Duration/contextFollow-up frequency and duration depend on cancer type and stage; policy provides specific context for colorectal and other cancers where CEA is used.

Other marker-specific frequency notes (recent revision)

Revision note placeholderPolicy revisions updated multiple marker-specific rows and frequencies; see updated policy table for full, test-specific frequency notes added in the 06/04/2025 revision.

Examples of recent updatesHE4 added for ovarian cancer indications; CA-125 and CA19-9 monitoring/workup indications adjusted; Inhibin (INHA) modified to include occult primary entries.

Action for providersRefer to the revised policy table and revision history for marker-specific frequency clarifications and new entries effective in the current document version.

Proprietary tests — frequency, usage, and reflex testing

Ova1Plus / Overa reflex behaviorOva1 is performed first and Overa is automatically conducted (reflex) when Ova1 results fall into an intermediate-risk category as part of the Ova1Plus process.

OvaWatch use caseOvaWatch may be considered for women with adnexal masses who are not planned for surgery to refine ovarian cancer risk assessment (uses biomarkers plus clinical factors).

BeScreened-CRC purposeBeScreened-CRC is a blood-based colorectal cancer screening test reporting 'negative' or 'positive' and is not intended to replace colonoscopy; frequency/coverage specifics are not provided in this extract.

Proprietary/procedure-code noteProprietary tests (e.g., Ova1Plus, OvaWatch, BeScreened-CRC) are listed with specific U/CPT codes in the policy table; providers should verify applicable coverage and coding prior to ordering.

Documentation Required

NCCN Advisory — Caution When Using Multibiomarker Assays for Adnexal Masses

NCCN guidance notes that multibiomarker assays for preoperative evaluation of an adnexal/pelvic mass have variable performance and the NCCN Panel does not recommend these biomarker tests for determining the status of an undiagnosed adnexal/pelvic mass. Providers should not use these assays as a substitute for referral: refer patients with suspected ovarian malignancy—especially those with adnexal masses—to an experienced gynecologic oncologist prior to surgery.

Biomarker tests (ROMA, Ova1, Overa, other multibiomarker assays) may be FDA-cleared for estimating risk when surgery is planned and a referral has not yet occurred, but coverage and clinical use should follow NCCN guidance and local authorization requirements.
Documentation of referral status or rationale for not referring must be included with prior authorization requests.

Documentation Required

Reflex Testing and Laboratory-Driven Reflex Algorithms

Laboratory reflex testing algorithms (e.g., Ova1 → Overa reflex when Ova1 yields an intermediate-risk result) are recognized but remain subject to prior authorization and documentation requirements. If reflex testing is performed by the submitting laboratory, the ordering provider must document the clinical indication and that reflex testing is part of the ordered diagnostic strategy.

Ova1Plus workflow: Ova1 performed first; Overa automatically reflexed for intermediate-risk results per manufacturer algorithm. Coverage/payment may be reviewed if reflex testing occurs without prior authorization or without documented indication.
When a lab performs reflex assays under a single order, claim submission must include the appropriate proprietary CPT/U-code(s) and clinical justification.

Documentation Required

Timing Requirements for Germ Cell Tumor Markers

Timing and sequencing requirements apply to germ cell tumor markers (e.g., AFP, serum hCG, LDH). Per ASCO guidance, measure AFP and hCG prior to orchiectomy to establish baseline, and again shortly after orchiectomy and before subsequent treatment. Measure AFP, hCG (and LDH when indicated) before chemotherapy cycles and at chemotherapy completion; continue surveillance measurements as recommended (ASCO recommends surveillance for up to 10 years after definitive therapy for nonseminomatous GCTs).

Measure AFP and hCG before orchiectomy and immediately after orchiectomy and prior to any additional therapy.
Measure AFP and hCG at the start of each chemotherapy cycle and at chemotherapy completion for stage II/III testicular nonseminomatous germ cell tumors.
Surveillance: repeated measurements per guideline (ASCO) — document dates relative to surgery and chemotherapy in the prior authorization/medical record.

Denial Risk

Neuroendocrine Tumor Markers — Restricted Use

Neuroendocrine tumor markers such as chromogranin A (CgA) and pancreastatin have limited utility and are not recommended for routine use to guide treatment. Results may be confounded by proton pump inhibitors (PPIs), atrophic gastritis, renal insufficiency, and other conditions; interpret cautiously and avoid routine ordering outside specialized or research settings.

Do not order CgA or pancreastatin routinely for PNETs or for treatment-guiding purposes; order only when results will influence management and after review of potential confounders (e.g., PPI use).
Document clinical rationale and medication history (including PPI use) when requesting authorization for neuroendocrine tumor markers.

Billing Rule

Procedure Code Coverage and Pre-Payment Review

Procedure codes for proprietary assays, unlisted multianalyte assays, and new/updated CPT U-codes may be subject to medical necessity review and prior authorization. Claims using unlisted or proprietary CPTs (or 81479/81599/84999) may trigger request for additional documentation and may be held for review prior to payment.

Common proprietary/procedural CPTs listed in this policy (examples): 0003U (Overa™), 0163U (BeScreened™-CRC), 0140U/0404U/0558U/0559U and other U-codes; 81500/81503/81538/81599; unlisted codes 81479, 81599, 84999.
Providers should submit full test name, lab performing the test, and clinical indication with the claim to reduce denials or payment delays.

Billing Rule

CPT Code Updates — Effective Date Notice

CPT coding updates effective 7/1/2025 include additions of CPT 0558U and 0559U and removal of CPT 83615 from the code list. Providers must use the current CPT code set when ordering and submitting claims and should confirm effective dates. Failure to use updated codes or referencing outdated policy versions may affect claim adjudication.

Added codes effective 07/01/2025: 0558U, 0559U.
Removed code: 83615 (no longer listed).
Always verify the current CPT list in this policy and on payer resources before claim submission.

Note

Policy Currency, Member Benefit Verification, and Government Coverage Precedence

This policy and the payer's laboratory policies are subject to change. Always verify the most current version of this policy and applicable lab policy online prior to ordering tests. Using outdated policy versions, failing to obtain required prior authorization, or not verifying member-specific benefits or applicable state/federal regulations (LCDs/NCDs) may result in denial of payment.

Policy disclaimer and authoritative copy: https://www.medmutual.com/LabPolicies — verify online before ordering.
If a government policy (NCD/LCD) or state Medicaid rule conflicts with this policy, the government policy takes precedence.

Documentation Required

Policy Revisions, Test Naming, and Coverage Changes

Coverage criteria, test naming, and CPT listings are periodically revised. Providers must reference the updated tables and CPT lists in the policy when submitting claims and include the specific test name, lab/manufacturer, and indication in prior authorization and claims documentation. Changes in covered indications (for example, removal of LDH as a tumor marker in this revision) may affect billing and coverage.

Revision notes: LDH section removed from serum tumor biomarker designation; other test/indication changes reflected in the revision history (see 06/04/2025).
Include the policy revision date or version when relevant documentation is provided to support medical necessity.

Note which biomarker panel was used when applicable.

Step Therapy

Timing for germ cell tumor markers (AFP, hCG) — perioperative and chemotherapy points

ASCO guidance specifies perioperative and chemotherapy time points for measurement of AFP and hCG in germ cell tumors: obtain pre‑orchiectomy baselines and measure at the start of each chemotherapy cycle and at treatment conclusion; follow recommended surveillance intervals.

Measure AFP and hCG before orchiectomy to establish baseline.
Measure at start of each chemotherapy cycle and at chemotherapy conclusion.

Documentation Required

LDT validation and CLIA requirements; note assay type

Tests referenced in the policy may be FDA‑approved assays or laboratory‑developed tests; LDTs must be validated by the performing laboratory and are regulated under CLIA '88 — ordering clinicians should note assay type and ensure documentation of validation when relevant.

LDTs are regulated under CLIA '88 as high‑complexity tests and require laboratory validation.
Ordering clinicians should document assay type (FDA‑cleared vs LDT) when relevant.

Billing Rule

Follow revised indications and coding after updates

After the policy updates, ordering clinicians should follow the revised indications and coding (refer to the updated tables and CPT lists) when submitting claims to ensure correct test selection and billing.

Terminology — common abbreviations and tumor marker terms

AFPAlpha-fetoprotein (AFP)

ALPAlkaline phosphatase (ALP)

AMHAnti-müllerian hormone (AMH)

B2MBeta-2 microglobulin (B2M)

CEACarcinoembryonic antigen (CEA)

PSAProstate specific antigen (PSA)

Biomarker indication categories

DiagnosticBiomarkers that aid in diagnosis or subclassification of disease; example: Philadelphia chromosome.

PrognosticBiomarkers associated with clinical outcomes independent of treatment (e.g., mutant p53).

PredictiveBiomarkers that predict activity of a specific therapy class (e.g., HER2 in breast cancer).

CompanionBiomarkers used to identify patients for whom a therapy has shown benefit (overlap with predictive category).

BNP / NT-proBNP — definition and clinical note

DefinitionBNP is an active peptide produced by cardiomyocytes; NT-proBNP is the inactive N-terminal fragment; both are cardiac peptides used as markers of cardiac dysfunction.

Clinical noteBNP or NT-proBNP concentrations may inform the degree of cardiac involvement in systemic light chain amyloidosis and multiple myeloma.

Testing contextThese markers are used in assessment or monitoring of cardiac involvement rather than as tumor-specific markers.

Serum free light chains — definition and clinical role

DefinitionSerum free light chains are quantitative measurements of unbound immunoglobulin light chains (kappa and lambda) in serum.

Clinical roleUsed to detect monoclonal production in plasma cell disorders and for diagnosis, prognosis, and monitoring of multiple myeloma and related disorders; may be used up to once per month for surveillance.

Testing combinationTypically ordered with serum protein electrophoresis and immunofixation for comprehensive evaluation.

Calcitonin — definition and clinical role

DefinitionCalcitonin is a serum marker primarily produced by thyroid C-cells and is the primary tumor marker for medullary thyroid carcinoma (MTC).

Clinical roleCalcitonin concentrations correlate with tumor mass and are used in evaluation and postoperative monitoring for MTC; routine screening for thyroid nodules is controversial.

Guidance noteThe American Thyroid Association cannot recommend for or against routine calcitonin screening in thyroid nodules due to lack of agreement on utility.

Serum free light chains — additional notes

Definition (additional)Serum free light chains measure kappa and lambda light chains; abnormalities in concentration and kappa/lambda ratio indicate monoclonal production.

Clinical applicationUsed for diagnosis and monitoring of plasma cell disorders, including oligosecretory multiple myeloma and AL amyloidosis; recommended with SPEP and immunofixation.

Frequency guidanceSurveillance frequency noted up to once per month in the policy for certain indications.

AFP-L3% / DCP — variant biomarker definitions and role

AFP-L3%AFP-L3% is a fraction/variant of AFP measured alongside total AFP (CPT 82107 includes AFP-L3 fraction).

DCP (PIVKA-II)Des-γ-carboxy prothrombin (DCP) is an AFP-related variant measured as an emerging HCC biomarker (CPT 83951 references DCP).

RoleAFP-L3% and DCP may provide greater specificity for HCC and are noted by societies as emerging/ promising adjuncts, though routine use as sole surveillance markers is limited.

Terminology adjustment — 'serum tumor markers' → 'serum biomarkers'

Terminology adjustmentPolicy terminology changed from 'serum tumor markers' to 'serum biomarkers' to better encompass serum-related markers more accurately described as biomarkers.

ImplicationTable headings and notes were updated to reflect broader terminology; providers should interpret policy rows using the 'serum biomarkers' heading.

Revision dateChange documented in the 06/04/2025 revision history.

Reassigned BNP/NT-proBNP initial diagnostic workup for systemic light chain amyloidosis to Troponin T section and clarified multiple monitoring/workup indications across biomarker rows.

2025-06-04coding_update

Added CPT codes 0558U and 0559U (effective 2025-07-01) and removed CPT code 83615 in the policy coding table.

2025-10-15policy_effective_dateLatest

Policy effective date set to 2025-10-15 reflecting the consolidated revisions and coding updates documented earlier in June 2025.